Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CMND

Clearmind Medicine Inc

Dec 13 • 04:00PM ET

1.47

Dollar change +0.01
Percentage change 0.91	%

Healthcare • Biotechnology • Canada • NASD

Peers: ATAI MNMD CYBN GHRS EOLS RLMD RLAY CMPS SAVA TCRT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.21	Insider Own	5.13%	Shs Outstand	3.98M	Perf Week	7.54%
Market Cap	6.52M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.01M	Perf Month	0.22%
Income	-8.44M	PEG	-	EPS next Q	-	Inst Own	22.16%	Short Float	6.38%	Perf Quarter	10.77%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.75	Perf Half Y	32.73%
Book/sh	0.87	P/B	1.69	EPS next Y	-	ROA	-133.31%	Short Interest	0.19M	Perf Year	-47.19%
Cash/sh	1.74	P/C	0.85	EPS next 5Y	-	ROE	-267.90%	52W Range	0.92 - 3.58	Perf YTD	-47.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.88%	ROI	-241.24%	52W High	-58.85%	Beta	-1.48
Dividend TTM	-	Quick Ratio	1.71	Sales past 5Y	0.00%	Gross Margin	-	52W Low	60.05%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.71	EPS Y/Y TTM	83.31%	Oper. Margin	-	RSI (14)	57.98	Volatility	8.90% 6.34%
Employees	-	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	75.84%	Payout	-	Rel Volume	0.68	Prev Close	1.46
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	255.29K	Price	1.47
SMA20	9.48%	SMA50	5.09%	SMA200	10.34%	Trades		Volume	174,069	Change	0.91%

Oct-10-24 08:07AM	Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site (GlobeNewswire)
Sep-16-24 04:06PM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire)
04:06PM	Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire)
Sep-12-24 08:20AM	Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment (GlobeNewswire)
Sep-06-24 07:55AM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
07:55AM	Loading…
07:55AM	Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
Aug-29-24 04:25PM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination (GlobeNewswire) -6.38%
04:25PM	Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment (GlobeNewswire)
Aug-25-24 09:54AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Aug-21-24 04:11PM	Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment (GlobeNewswire) +6.55% +6.15%
Aug-16-24 04:14PM	Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders (GlobeNewswire)
Aug-06-24 08:57AM	SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug (GlobeNewswire)
08:57AM	Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug (GlobeNewswire)
Jul-31-24 07:44AM	Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research (GlobeNewswire)
Jul-19-24 07:55AM	Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product (GlobeNewswire)
09:02AM	Loading…
Jul-16-24 09:02AM	Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism (GlobeNewswire) -17.57%
06:03AM	SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss (GlobeNewswire)
06:03AM	Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss (GlobeNewswire)
Jul-12-24 08:02AM	Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine Israel 2024 Conference (GlobeNewswire) +5.59%
Jun-28-24 07:55AM	Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment (GlobeNewswire) +25.37%
Jun-20-24 07:57AM	Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment (GlobeNewswire)
Jun-17-24 11:52AM	CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 (InvestorPlace)
Jun-11-24 07:44AM	Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink (GlobeNewswire)
May-10-24 08:24AM	Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product (GlobeNewswire) -6.67%
May-07-24 07:46AM	Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment (GlobeNewswire) +26.50%
Apr-30-24 04:15PM	Clearmind Applies to Cease Being a Reporting Issuer in Canada (GlobeNewswire)
Apr-17-24 07:49AM	Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders (GlobeNewswire)
Apr-10-24 07:17AM	Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders (GlobeNewswire)
Apr-09-24 08:07AM	Clearmind Medicine CEO Issues Letter to Shareholders (GlobeNewswire) +17.86%
Mar-27-24 09:12AM	Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression (GlobeNewswire)
08:55AM	Loading…
08:55AM	SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression (GlobeNewswire)
Mar-19-24 07:55AM	Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China (GlobeNewswire)
Mar-13-24 08:14AM	Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial (GlobeNewswire) -7.48%
07:30AM	Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange (GlobeNewswire)
Feb-27-24 07:58AM	SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
07:58AM	Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
Feb-26-24 10:37AM	Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours (News Direct) -7.98%
Feb-23-24 07:06AM	Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder (GlobeNewswire)
Feb-20-24 07:14AM	SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire) +14.07%
07:14AM	Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire)
Feb-11-24 01:59PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-05-24 07:51AM	Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China (GlobeNewswire)
Feb-01-24 08:15AM	Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center (GlobeNewswire) +20.28%
Jan-16-24 12:20PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND) (ACCESSWIRE) -5.88%
11:19AM	Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement (GlobeNewswire)
Jan-11-24 09:28AM	Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement (GlobeNewswire) -43.00%
08:53AM	Why Is Clearmind Medicine (CMND) Stock Down 24% Today? (InvestorPlace)
Jan-10-24 07:18AM	Clearmind Medicine Completed Type A Meeting with the FDA (GlobeNewswire) +41.55%
Jan-04-24 07:18AM	SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments (GlobeNewswire) -6.51%
07:18AM	Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments (GlobeNewswire)
Dec-14-23 08:26AM	Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards (GlobeNewswire)
Dec-05-23 01:09PM	Why Is Clearmind Medicine (CMND) Stock Up 50% Today? (InvestorPlace) +14.10%
08:47AM	Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment (GlobeNewswire)
Dec-01-23 08:14AM	Weight loss MEAI: Clearmind Medicines Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial (GlobeNewswire) +18.29%
Nov-28-23 08:25AM	Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment (GlobeNewswire) +10.34%
Nov-27-23 08:55AM	Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures (GlobeNewswire) -16.21%
Nov-21-23 08:15AM	Clearmind Medicine Announces 1-for-30 Reverse Share Split (GlobeNewswire)
Nov-17-23 04:15PM	Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance (GlobeNewswire) +7.36% -8.39%
Nov-15-23 07:37AM	Clearmind Medicine Announces Shareholders Meeting Results (GlobeNewswire)
Nov-09-23 09:20AM	Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities (GlobeNewswire) -6.23%
Oct-05-23 09:00AM	Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th (GlobeNewswire) -5.70%
Sep-28-23 09:00AM	Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th (Newsfile)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-19-23 10:30AM	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND) (ACCESSWIRE)
Sep-18-23 12:16PM	Clearmind Medicine Closes US$2.25 Million Public Offering (GlobeNewswire)
Sep-14-23 09:23AM	Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering (GlobeNewswire) -54.14%
Sep-06-23 09:20AM	Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder (GlobeNewswire) +11.14%
Aug-14-23 08:25AM	Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company (GlobeNewswire) -8.49%
Aug-01-23 09:00AM	SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S. (GlobeNewswire)
09:00AM	Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio (GlobeNewswire)
Jul-17-23 04:15PM	Clearmind Medicine Announces Share-Based Payment for the Company's Consultants (GlobeNewswire)
Jul-11-23 08:30AM	Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board (GlobeNewswire)
Jun-16-23 09:05AM	SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire)
09:05AM	Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire)
Jun-09-23 09:30AM	Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity (GlobeNewswire)
May-22-23 08:30AM	Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder (GlobeNewswire)
May-19-23 04:15PM	Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-17-23 09:00AM	Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity (GlobeNewswire)
May-12-23 09:00AM	Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder (GlobeNewswire) +9.51%
May-09-23 04:15PM	Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants (GlobeNewswire)
May-08-23 08:30AM	Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam (GlobeNewswire)
May-02-23 08:30AM	Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial (GlobeNewswire)
Apr-27-23 08:30AM	Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial (GlobeNewswire) -15.03%
Apr-21-23 08:30AM	SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression (GlobeNewswire)
08:30AM	Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression (GlobeNewswire)
Apr-20-23 05:37AM	Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial (GlobeNewswire) +13.13%
Apr-10-23 11:00AM	Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ: CMND) (ACCESSWIRE) +11.81%
Apr-06-23 04:15PM	Clearmind Medicine Closes US$3.5 Million Public Offering (GlobeNewswire)
Apr-04-23 09:00AM	Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering (GlobeNewswire) -62.21%
Mar-16-23 08:30AM	Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder (GlobeNewswire) -5.88%
Mar-14-23 08:55AM	Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board (GlobeNewswire) -10.12%
Feb-22-23 08:00AM	SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds (GlobeNewswire)
08:00AM	Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds (GlobeNewswire)
Feb-15-23 08:30AM	SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US (GlobeNewswire)
08:30AM	Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US (GlobeNewswire)
Feb-14-23 08:30AM	Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv (GlobeNewswire) -6.46%
Feb-08-23 08:30AM	Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity (GlobeNewswire)
Jan-31-23 09:00AM	Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound (GlobeNewswire)
Jan-25-23 08:30AM	Hebrew University' Yissum and Israeli Biotech Clearmind Medicines Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023 (GlobeNewswire)
Jan-19-23 09:00AM	Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalems Tech Transfer Company, Yissum (GlobeNewswire)

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMND

Clearmind Medicine Inc

Upgrade your FINVIZ experience